BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 11801458)

  • 21. Recent advancements in the treatment of chronic myelogenous leukemia.
    O'Dwyer ME; Mauro MJ; Druker BJ
    Annu Rev Med; 2002; 53():369-81. PubMed ID: 11818480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting.
    Ruiz-Argüelles GJ; Gomez-Almaguer D; Steensma DP
    Am J Hematol; 2012 Sep; 87(9):941. PubMed ID: 22674687
    [No Abstract]   [Full Text] [Related]  

  • 23. [Dose-reduced conditioning before allogeneic stem cell transplantation: principles, clinical protocols and preliminary results].
    Schmid C; Weisser M; Ledderose G; Stötzer O; Schleuning M; Kolb HJ
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2186-92. PubMed ID: 12397547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia.
    Perz JB; Khorashad JS; Marin D; Apperley JF; Olavarria E
    Haematologica; 2006 Aug; 91(8):1145-6. PubMed ID: 16870551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Interferon in the treatment of Philadelphia-positive chronic myeloid leukemia].
    Morra E; Alimena G; Lazzarino M; Liberati AM; Montefusco E; Inverardi D; Bernasconi P; Mancini M; Donti E; Senatore M
    Haematologica; 1990; 75 Suppl 4():33-40. PubMed ID: 1705912
    [No Abstract]   [Full Text] [Related]  

  • 26. [Treatment strategies for chronic myeloid leukemia].
    Jinnai I
    Rinsho Ketsueki; 2005 Jan; 46(1):1-6. PubMed ID: 16708910
    [No Abstract]   [Full Text] [Related]  

  • 27. [Successful attainment of the third chronic phase by autologous peripheral blood stem cell transplantation and imatinib in a patient with chronic myeloid leukemia].
    Tabata S; Ohno T; Tomo K; Hishita T; Hada S; Mizumoto T; Furukawa H
    Rinsho Ketsueki; 2003 May; 44(5):313-7. PubMed ID: 12822405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current use of imatinib in the treatment of chronic myeloid leukemia.
    O'Dwyer M
    Haematologica; 2003 Mar; 88(3):241-4. PubMed ID: 12651257
    [No Abstract]   [Full Text] [Related]  

  • 29. Cyclophosphamide/GM-CSF priming in autotransplant therapy for CML.
    McGlave P; Bhatia R; Verfaillie C
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S65-6. PubMed ID: 8769706
    [No Abstract]   [Full Text] [Related]  

  • 30. The management of chronic myeloid leukaemia--a case history.
    Sureda A; Hernández-Bronchud M
    Ann Oncol; 1997 Jan; 8(1):91-6. PubMed ID: 9093713
    [No Abstract]   [Full Text] [Related]  

  • 31. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis.
    Palandri F; Amabile M; Rosti G; Bandini G; Benedetti F; Usala E; Angelucci E; Tiribelli M; Fanin R; Martinelli G; Baccarani M
    Bone Marrow Transplant; 2007 Feb; 39(3):189-91. PubMed ID: 17211436
    [No Abstract]   [Full Text] [Related]  

  • 32. Successful paternity of twins following bone marrow transplantation with busulfan, melphalan and cyclophosphamide conditioning.
    Shepherd JD; Hoar DI; Keown PA; Phillips GL
    Bone Marrow Transplant; 1996 Mar; 17(3):461-2. PubMed ID: 8704708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shin HJ; Chung JS; Cho GJ
    Bone Marrow Transplant; 2005 Nov; 36(10):917-8. PubMed ID: 16113662
    [No Abstract]   [Full Text] [Related]  

  • 34. [Total body irradiation in hematology: clinical indications and prospects].
    Corvò R
    Recenti Prog Med; 1999 Nov; 90(11):601-4. PubMed ID: 10608150
    [No Abstract]   [Full Text] [Related]  

  • 35. [Therapeutic efficacy of hematopoietic stem cell transplantation in patients with chronic myelogenous leukemia].
    Liu QF; Fan ZP; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Nov; 24(11):1227-9, 1241. PubMed ID: 15567763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chronic myeloid leukemia as a model for the development and therapeutic use of tyrosine kinase inhibitors].
    López-Karpovitch X
    Rev Invest Clin; 2003; 55(2):191-5. PubMed ID: 12827926
    [No Abstract]   [Full Text] [Related]  

  • 37. Imatinib alone and in combination for chronic myeloid leukemia.
    Druker BJ
    Semin Hematol; 2003 Jan; 40(1):50-8. PubMed ID: 12563611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating children with chronic myeloid leukemia in the imatinib era: a therapeutic dilemma?
    Thornley I; Perentesis JP; Davies SM; Smith FO; Champagne M; Lipton JM
    Med Pediatr Oncol; 2003 Aug; 41(2):115-7. PubMed ID: 12825214
    [No Abstract]   [Full Text] [Related]  

  • 39. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
    Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
    Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imatinib results in better quality of life for CML patients than interferon/Ara-C.
    J Support Oncol; 2003; 1(1):77. PubMed ID: 15352651
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.